S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Qiagen Stock Forecast, Price & News

-0.15 (-0.32%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.29 million shs
Average Volume
807,665 shs
Market Capitalization
$10.60 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Stock Forecast (MarketRank)

Overall MarketRank

1.69 out of 5 stars

Medical Sector

934th out of 1,432 stocks

Biological Products, Except Diagnostic Industry

142nd out of 217 stocks

Analyst Opinion: 2.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
Qiagen logo

About Qiagen (NYSE:QGEN)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

QGEN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$359.19 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.87 billion
Cash Flow
$3.16 per share
Book Value
$12.27 per share


Free Float
Market Cap
$10.60 billion

Qiagen Frequently Asked Questions

Should I buy or sell Qiagen stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Qiagen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares.
View analyst ratings for Qiagen
or view top-rated stocks.

What is Qiagen's stock price forecast for 2022?

7 brokerages have issued 12-month price targets for Qiagen's shares. Their QGEN stock forecasts range from $49.00 to $60.00. On average, they anticipate Qiagen's share price to reach $54.13 in the next year. This suggests a possible upside of 16.0% from the stock's current price.
View analysts' price targets for Qiagen
or view top-rated stocks among Wall Street analysts.

How has Qiagen's stock performed in 2022?

Qiagen's stock was trading at $55.58 at the start of the year. Since then, QGEN stock has decreased by 16.0% and is now trading at $46.68.
View the best growth stocks for 2022 here

When is Qiagen's next earnings date?

Qiagen is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Qiagen

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) posted its quarterly earnings results on Tuesday, April, 26th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.09. The business had revenue of $628.39 million for the quarter, compared to the consensus estimate of $589.95 million. Qiagen had a net margin of 26.61% and a trailing twelve-month return on equity of 20.71%. During the same quarter last year, the company earned $0.66 EPS.
View Qiagen's earnings history

What guidance has Qiagen issued on next quarter's earnings?

Qiagen issued an update on its FY22 earnings guidance on Tuesday, April, 26th. The company provided earnings per share guidance of $2.14 for the period, compared to the consensus estimate of $2.06. The company issued revenue guidance of $2.12 billion, compared to the consensus revenue estimate of $2.10 billion.

Who are Qiagen's key executives?

Qiagen's management team includes the following people:
  • Mr. Thierry Bernard, CEO, MD & Member of Management Board (Age 57, Pay $2.02M)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 53, Pay $1.18M)
  • Mr. Antonio Santos, Sr. VP & Head of Global Operations
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Ms. Stephany Foster, Sr. VP & Head of HR
  • Dr. Thomas Schweins, Sr. VP of Life Science Bus. Area
  • Dr. Thomas Theuringer, Sr. Director & Head of External Communications
  • Mr. Jean-Pascal Viola, Sr. VP & Head of Molecular Diagnostics Bus. Area
  • Dr. Jonathan G. Sheldon Ph.D., Sr. VP of Qiagen Digital Insights Bus. Area (Age 50)
  • Mr. Thomas Neidert, VP of Global Treasury

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen CEO Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among Qiagen's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $46.68.

How much money does Qiagen make?

Qiagen (NYSE:QGEN) has a market capitalization of $10.60 billion and generates $1.87 billion in revenue each year. The company earns $359.19 million in net income (profit) each year or $2.559990 on an earnings per share basis.

How many employees does Qiagen have?

Qiagen employs 6,000 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for Qiagen is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at [email protected], or via fax at 31-77-355-6658.

This page (NYSE:QGEN) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.